SCHEMBL209492

SCHEMBL209492

O=C(NCC(F)(F)F)c1ccc(-c2cc(Cl)c(CC3CCN(C4CCCCC4)C3=O)c(Cl)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.41
ULK1 O75385 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
MLYCD O95822 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
CHRM4 P08173 2/20 0.34
GCGR P47871 3/20 0.34
ACKR3 P25106 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CTSS P25774 1/20 0.34
MCHR1 Q99705 3/20 0.33
ACP1 P24666 1/20 0.33
IP6K1 Q92551 1/20 0.33
GIPR P48546 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210257 0.88 HSD11B1 (0.43) HSD11B1KMT2AMEN1
SCHEMBL15204423 0.88 HSD11B1 (0.40) HSD11B1MCHR1
SCHEMBL209956 0.87 HSD11B1 (0.45) HSD11B1HDAC6
SCHEMBL209301 0.86 HSD11B1 (0.42) HSD11B1KMT2AMEN1CHRM1MCHR1
SCHEMBL210959 0.86 HSD11B1 (0.42) HSD11B1KMT2AMEN1CHRM1MCHR1
SCHEMBL209754 0.86 HSD11B1 (0.45) HSD11B1KMT2AMEN1
SCHEMBL211427 0.85 HSD11B1 (0.44) HSD11B1KMT2AMEN1
SCHEMBL2722387 0.85 CNR2 (0.46) HSD11B1KMT2A
SCHEMBL2720661 0.85 HRH3 (0.48)
SCHEMBL209985 0.84 CNR2 (0.45) HSD11B1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885ULK1 2327/4885JAK2 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.